What this is
- How it works
- How it works isn't classified yet
- How it’s given
- “A single dose of Calfactant administered by pacifier interface by inhalation via the Infasurf Aero nebulizer at 6ml/kg.”In the company’s words, NCT05960929 on ClinicalTrials.gov
- Tested for
- Respiratory Distress Syndrome (Neonatal), Intubation Complication, Death; Neonatal
- Main trialPhase 3
- “The purpose of this clinical study is to determine the effectiveness and safety of Infasurf® administered through the InfasurfAero™, a novel oral airway delivery device specifically designed to give Infasurf in a less complicated way and without the need for a breathing tube or interrupting nasal respiratory support.”In the company’s words, NCT05960929 on ClinicalTrials.gov
- Other names
- Infasurf · Calfactant · Infasurf Aero
Coming up0
No dates coming up.
Changes0
Last 90 daysNo changes yet. We started recording changes on 6 Nov 2026.
Trials2
| Trial | Phase | Completes | What it tests |
|---|---|---|---|
| Phase 3Recruiting | 1 Jan 2026 | InfasurfAero™ Versus Sham Treatment in Preterm Newborns With RDS | |
| Phase 3Completed | 1 Jun 2018 | Comparison of Aerosol Delivery of Infasurf to Usual Care in Spontaneously Breathing RDS Patients |
A trial in both registries shows both numbers.
About
- Sources
- ClinicalTrials.gov updated 18 Nov 2026 · EU trials register (CTIS) updated 18 Nov 2026 · openFDA updated 17 Nov 2026